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First lung transplantation as a treatment of a patient supported 
with extracorporeal membrane oxygenation (ECMO) 
after COVID-19 in Poland
Abstract
A 44-year-old male with no history of underlying diseases was referred to academic hospital due to ARDS with confirmed SARS-
CoV-2 infection after 7 days of mechanical ventilation. Veno-venous (VV) extracorporeal membrane oxygenation (ECMO) was 
initiated as no improvement was noted in prone position. Mechanical ventilation was continued with TV of 3–4 mL/kg. A gradual 
decline of static lung compliance was observed from baseline 35 mL/cm H20 to 8 mL/cm H2O. The chest CT scan revealed exten-
sive ground-glass areas with a significant amount of traction bronchiectasis after 3 weeks since admission. When the patient 
was negative for SARS-CoV-2 during the 4th week of ECMO, the decision to perform an emergency lung transplantation (LTx) was 
made based on the ongoing degradation of lung function and irreversible damage to lung structure. The patient was transferred 
to the transplant center where he was extubated, awaiting the transplant on passive oxygen therapy and ECMO. Double lung 
transplantation was performed on the day 30th of ECMO. Currently, the patient is self-reliant. He does not need oxygen therapy 
and continues physiotherapy. 
ECMO may be life-saving in severe cases of COVID-19 ARDS but some of these patients may require LTx, especially when wean-
ing proves impossible. VV ECMO as a bridging method is more difficult but ultimately more beneficial due to insufficient number 
of donors, and consequently long waiting time in Poland.
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Introduction
The severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) causes respiratory 
infection of variable severity known as corona-
virus disease (COVID-19). Some of the patients 
with acute respiratory failure may require ex-
tracorporeal membrane oxygenation (ECMO) 
[1]. ECMO may not only be a salvage therapy 
in profound hypoxemia and an efficient tool to 
provide lung-protective ventilation but may also 
serve as an effective bridge to lung transplanta-
tion (LTx) [2]. 
Case presentation
A 44-year-old male with no history of under-
lying chronic illness was admitted to the intensive 
care ECMO unit due to acute respiratory failure 
caused by COVID-19 infection. Detailed course 
of the disease is presented in Figure 1. He was 
treated with remdesivir, convalescent plasma 
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and ritonavir + lopinavir with no improvement. 
He required invasive mechanical ventilation for 
7 days with the tidal volume of 6 mL/kg, positive 
end-expiratory pressure (PEEP) 14 cm H2O, fre-
quency of 22/min and fraction of inspired oxygen 
(FiO2) 1.0. After placing him in prone position, 
minor improvement of oxygenation was noted 
with a marked increase of arterial partial pressure 
of carbon dioxide (PaCO2) and a respiratory acido-
sis. Veno-venous (VV) ECMO with femoro-jugular 
access was instituted due topersistent respira-
tory acidosis, oxygenation index of 80 mm Hg 
and discouraging response to proning. Me-
chanical ventilation was switched to protective 
settings. His hemodynamic status improved 
significantly. Acute kidney injury resolved after 
a single course of continuous renal-replacement 
therapy. A gradual loss of static lung compliance 
was observed from 35 mL/cm H2O on admission 
to the final 8 mL/cm H2O. Transient hemorrhage 
to the left main bronchus ceased after tapering 
heparin infusion to the activated partial throm-
boplastin time (APTT) level of around 40 sec. 
(baseline 22 sec.). High-resolution computed to-
mography (HRCT) scan of the thorax revealed ex-
tensive ground-glass opacities with a significant 
amount of traction bronchiectasis. A detailed 
depiction is presented in Figure 2. The patient 
turned negative for SARS-CoV-2 after 3 weeks 
of treatment. He was awake, alert and cooper-
ative after cessation of sedation. The decision 
to perform an emergency lung transplantation 
was made during the fourth week on ECMO 
due to irreversible lung failure. The man was 
subsequently transferred to the transplant cen-
ter (blood flow 3.0 L/min) while on mechanical 
ventilation and ECMO. He was extubated in the 
following days according to our awake ECMO 
protocol. Sequential double lung transplantation 
was performed on day 30th since the initiation of 
ECMO. The procedure itself took place while the 
patient was still treated with ECMO support. He 
was hemodynamically unstable with periodical 
support of catecholamines but with left ventricle 
ejection fraction (LVEF) at 65% without pulmo-
nary hypertension. Pulmonary artery catheter 
Swan-Ganz (PAC), which is standard monitoring 
in LTx, was not placed in the patient because 
of inadequate measurement during VV-ECMO. 
A transesophageal echocardiography (TEE) probe 
was placed for TEE monitoring. Anesthesia and 
analgesia were approached in a manner typical 
Figure 2. A, B. High-resolution computed tomography of the thorax presenting significant amount of lungs subjected to inflammation and fibrosis; 
C. Chest X-ray of the patient treated with invasive ventilation alone due to COVID-19; D. Chest X-ray at discharge from the lung transplant facility
A B
C D
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of the lung transplantation procedure. The pa-
tient was intubated with a left-sided Robertshaw 
double-lumen tube (DLT). The most critical steps 
during lung transplantation was induction of 
anesthesia, pulmonary artery clamping, graft 
implantation and reperfusion. Initial ventilator 
settings were set according to lung protective 
ventilation strategy. VV-ECMO was continued 
during the whole procedure. Inhaled nitric oxide 
(iNO) was administered — 60 ppm. Pleural cavi-
ties were accessed via mini-thoracotomy through 
the 5th intercostal space, but higher access seems 
to be more reasonable as those patients have their 
diaphragm located higher. Typical preparation of 
the lungs and hila was carried out. The visceral 
pleura was very fragile as well as easy to bleed 
even at careful preparation due to dense vascular 
net. Morphology of the lungs presented atypical 
findings of cysts filled with dense hemolyzed 
blood as depicted in Figure 3. Histopathological 
findings of the lungs were presented in Figure 
4. ECMO was explanted after the implantation 
of both lungs. The authors of this work advise to 
pay special attention to the fact that respiratory 
infection in the course of COVID-19 may shrink 
the volume of the chest cavity. Proper sizing of 
1:1 or less is crucial during qualification. During 
the procedure, there was a need for surgical 
lung volume reduction using linear automatic 
staplers. The authors took the liberty of more 
liberal size-matching of the lungs due to critical 
condition of the patient and increasing risk of EC-
MO-related complications. The man was admit-
ted to the lung transplantation ward intubated, 
in stable condition with pressure controlled syn-
chronized intermittent mechanical ventilation 
(PC-SIMV) with PEEP of 8 mm H2O, frequency 
of 12/min and peak pressure 24 mm H2O. 
Immunosuppression was initiated at the be-
ginning of the operation with venous infusion of 
tacrolimus as well as 1 g of methylprednisolone 
followed by 125 mg every 12 hours 3 times. Stan-
dard maintenance immunosuppression con-
sisted of tacrolimus (target concentration of 
10-12 ng/mL), mycofenolate mofetil twice a day 
and prednisolone. The rest of the drugs were ad-
ministered according to standard protocol. The 
patient was extubated on the third postoperative 
day (POD). Extensive physical rehabilitation was 
implemented since the first POD. First two weeks 
were uneventful except for partial impairment 
of the right common fibular nerve. The patient 
obtained 65% of predicted forced expiratory vol-
ume in 1 second 4 weeks after the double lung 
transplantation. Proper healing was observed 
under bronchoscopic evaluations. He was dis-
charged home.
We report this case now knowing that the 
patient has already reached a 3-month follow-up 
in general good condition with full respiratory 
capacity, as we can assess the treatment to be 
successful when the patient achieves this stage. 
Discussion
A significant proportion of patients with 
COVID-19 develop respiratory failure ranging 
from mild dyspnea treated with oxygen therapy 
to severe acute respiratory distress syndrome 
(ARDS) fulfilling criteria for ECMO support. 
Experience with extracorporeal gas exchange 
gathered in 2009 and 2010 together with the 
first randomized trial revealing benefit of ECMO 
in ARDS [3] led to its widespread use in the 
intensive care. However, the outcome of ECMO 
in SARS-CoV-2-associated ARDS has not been 
clearly defined yet. The death in COVID-19 may 
arise predominantly from the multiorgan failure 
amidst the cytokine storm [4] with a very little 
fraction of patients dying of profound hypoxemia 
[5]. Therefore, ECMO is indicated mainly in sub-
jects with predominant respiratory failure, pref-
erably without the involvement of other organs 
[1]. The ultimate result of ECMO is determined 
by the ability to provide more protective mechan-
ical ventilation and appropriate gas exchange on 
the one hand and the risk of complications and 
the chance of good long-term lung function on 
the other.
Figure 3. A photograph of the recipient’s native lung minutes after 
the explantation
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Figure 4. Histopathological examinations of native lungs: interstitial pneumonia with fibrosis; focal proliferation of type 2 pneumocytes; focal squa-
mous metaplasia of bronchial epithelium; obliteration of some small arterioles; organized exudate in some of the alveoli
Intense lung fibrosis has been described in 
some COVID-19 patients ending up in a severely 
decreased functional capacity [6]. This case has 
shown that advanced fibrosis may develop over 
as little as 4-5 weeks despite lung-protective 
ventilation. It also demonstrates that patients 
may require emergency lung transplantation in 
order to be weaned off ECMO. It is also possible 
that prolonged period of non-invasive ventila-
tion with increasing both respiratory effort and 
support levels may have led to progression of the 
patient’s self-inflicted lung injury [7]. Simultane-
ously, proper assessment of neurological func-
tion and obtaining an informed consent for the 
transplantation warrants extubation which may 
be facilitated with ECMO. Therefore, this case is 
a proof that ECMO may be a valuable option as 
a bridge to transplant in selected patients with 
COVID-19 ARDS. 
However, careful consideration must be 
applied when it comes to qualifying patients 
to be treated by means of lung transplantation 
[8]. The patient should present no other signif-
icant organ failure. Decision to perform lung 
transplantation among individuals qualified 
due to postCovid-19 respiratory failure should 
be made timely. It is in the patients’ best inter-
ests to be able to survive without a transplant. 
Hence, infected lungs should be allowed to 
heal first, regardless of the extent of respiratory 
support including ECMO. The presented case 
is the first double lung transplantation due 
to COVID-19 among all lung transplantations 
performed in our facility as well as in Poland. 
The authors would like to underline that at the 
date of double lung transplantation (end of July 
2020), there was only 5 similar cases described 
in the literature. There are reports of 5 lung 
transplantations performed shortly after ob-
taining the positive-turned negative virology in 
China [9], [10]even those whose nucleic acid test 
results had turned negative and those receiving 
maximal medical support, have been noted to 
progress to irreversible fatal respiratory fail-
ure. Lung transplantation (LT. Similarly to our 
patient, all of them required ECMO as a bridge 
to lung transplantation. In comparison to Chen 
et al., our patient had ECMO explanted in the 
surgical theatre after the procedure with a good 
outcome [9]even those whose nucleic acid test 
results had turned negative and those receiving 
maximal medical support, have been noted to 
progress to irreversible fatal respiratory failure. 
Lung transplantation (LT. Another interesting 
difference is that Chen’s patients were operated 
via Clamshell approach, while our patient un-
derwent the procedure through double minitho-
racotomy. This finding is important because it is 
more beneficial for the patient mostly in terms 
of upcoming extensive physiotherapy. Two sub-
jects described by Han et al. also required ECMO 
as a bridge to lung transplantation. They were 
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operated on with a good outcome [10] and had 
the ECMO therapy withdrawn on respectively 
the fifth and second POD. 
The great advantage of our case report is that 
it depicts the young patient without comorbidi-
ties whose lungs were permanently damaged to 
the point of needing lung transplantation. Such 
a finding is supported by a paper published by 
Bharat et al. who described successful lung trans-
plantation of the 43-year-old male patient with 
well-controlled type 2 diabetes mellitus despite 
his pre-transplant course being more complicated 
than in case of our patient. Bharat et al. also re-
ported even younger case (a 28-year-old woman) 
[11]. However, it is worth mentioning that she 
was receiving immunosuppressive treatment due 
to her preexisting conditions. In our facility, it 
is vital that potential lung transplant candidate 
obtains negative SARS-CoV-2 real-time poly-
merase chain reaction (RT-PCR) test result. This 
condition was met before listing of our patient 
as well as the next patient transplanted by our 
team due to post-COVID-19 ARDS several weeks 
later. Such a thing was not necessary in Klinikum 
Klagenfurt am Wörthersee, where the first case 
of lung transplantation for a patient with a per-
sistently positive SARS-CoV-2 RT-PCR test result 
took place [12]. A 44-year-old woman with mild 
psoriatic arthritis and idiopathic CD4 lymphocy-
topenia became a lung transplant recipient as it is 
reported by Lang et al. from the aforementioned 
Austrian facility. This case report is particularly 
important because it shows certain limitation of 
the RT-PCR testing. This method may produce 
a positive result based on nucleic acid segments 
of residual virus without actual infectivity as 
indicated by exceptionally high RT-PCR cycle 
threshold values. The Austrian team determined 
that there was no active infection based on neg-
ative Vero cell cultures result. The authors of 
this paper advice careful consideration and very 
thorough process of excluding active infection 
among patients with positive RT-PCR result for 
SARS-CoV-2. ECMO VV in case of our patient was 
safely discontinued at the end of the procedure. 
It shows that since the first POD such patients 
do not have to endure the risk of adverse effects 
associated with this therapy either. Poland among 
many countries is facing the insufficient number 
of lung donors, especially during the time of pan-
demics. Therefore, VV ECMO is more beneficial 
despite being the more challenging in terms of 
patient maintenance as a potential recipient has 
a greater chance of being successfully bridged to 
lung transplantation in comparison to VA ECMO 
patient.
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